SOST and hypertensive disorder: Lower circulating sclerostin was associated with an increased risk of hypertension (OR 1.09 per SD decrease in sclerostin [95% CI 1.04–1.15]; P = 7.93 × 10−4), whereas the effects are generally attenuated for other outcomes in the cis+trans analyses (Supplementary Figures 7 and 8, http://onlinelibrary.wiley.com/doi/10.1002/art.42538).